News

Lukang News

Good News! The First in China! Lukang Pharma's Self-Developed Pet-Specific Drug was Approved as a National Class II New Veterinary Drug!

On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

2024-04-28

LUKANG PHARMA carries out a series of activities to celebrate Women's Day on March 8th

Spring begins in March, and everything blooms. In order to deeply implementing the spirit of 20th CPC National Congress and new development concept, build an happiness enterprise to lead and inspire female staff play the role of "Half the Sky", LUKANG PHARMA has organized more than 40 labour unions to carry out a series of activities in themes of celebrating the Women's Day.

2024-03-08

Good news! Lukang Pharma Ranked on China Pharmaceutical Industry Top 100 List

On Nov. 17-19, 2023 China Pharmaceutical Industry Development Conference was held in Beijing. During the 40th National Pharmaceutical Industry Information Conference & 2022 Top 100 China Pharmaceutical Industry Forum, the highly anticipated "2022 China Pharmaceutical Industry Top 100 List" was published, Lukang pharma entered the China Pharmaceutical Industry Top 100 List again.

2023-11-28

The company has successfully passed the re-certification of the National Enterprise Technology Center

Recently, Lukang pharma successfully passed the re-certification of the National Enterprise Technology Center with "excellent" results.

2023-11-06

Good news! Nifedipine Sustained-release Tablets (Ⅰ) of Lukang Saite Company passed the consistency evaluation of generic drugs!

The application for consistency evaluation of Nifedipine Sustained-release Tablets (I) (10mg) of Lukang Saite Company was approved by NMPA and was officially approved on August 31.

2023-09-12

Good news! Lukang Pharm's first anti-rheumatoid arthritis product got Marketing Authorization!

The company's Tofacitinb Citrate Tables (5mg) was obtained drug registration certificate (No.: 2023S01222) approved by NMPA on Aug. 01, which was the first anti-rheumatoid arthritis product got Marketing Authorization

2023-09-01

< 1234 >

Lukang News

2024-04-28

Good News! The First in China! Lukang Pharma's Self-Developed Pet-Specific Drug was Approved as a National Class II New Veterinary Drug!

On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

2024-03-08

LUKANG PHARMA carries out a series of activities to celebrate Women's Day on March 8th

Spring begins in March, and everything blooms. In order to deeply implementing the spirit of 20th CPC National Congress and new development concept, build an happiness enterprise to lead and inspire female staff play the role of "Half the Sky", LUKANG PHARMA has organized more than 40 labour unions to carry out a series of activities in themes of celebrating the Women's Day.

2023-11-28

Good news! Lukang Pharma Ranked on China Pharmaceutical Industry Top 100 List

On Nov. 17-19, 2023 China Pharmaceutical Industry Development Conference was held in Beijing. During the 40th National Pharmaceutical Industry Information Conference & 2022 Top 100 China Pharmaceutical Industry Forum, the highly anticipated "2022 China Pharmaceutical Industry Top 100 List" was published, Lukang pharma entered the China Pharmaceutical Industry Top 100 List again.

2023-11-06

The company has successfully passed the re-certification of the National Enterprise Technology Center

Recently, Lukang pharma successfully passed the re-certification of the National Enterprise Technology Center with "excellent" results.

2023-09-12

Good news! Nifedipine Sustained-release Tablets (Ⅰ) of Lukang Saite Company passed the consistency evaluation of generic drugs!

The application for consistency evaluation of Nifedipine Sustained-release Tablets (I) (10mg) of Lukang Saite Company was approved by NMPA and was officially approved on August 31.

2023-09-01

Good news! Lukang Pharm's first anti-rheumatoid arthritis product got Marketing Authorization!

The company's Tofacitinb Citrate Tables (5mg) was obtained drug registration certificate (No.: 2023S01222) approved by NMPA on Aug. 01, which was the first anti-rheumatoid arthritis product got Marketing Authorization
< 1234 >